LC-Plasma for Preventing URTIs and Reducing Symptoms

Launched by RDC CLINICAL PTY LTD · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a product called LC-Plasma to see if it can help prevent upper respiratory tract infections (URTIs) in healthy adults. URTIs are common illnesses that affect the nose and throat, like colds. The researchers will compare LC-Plasma to a placebo (a pill that looks the same but has no active ingredients) to find out if taking LC-Plasma daily for 24 weeks can reduce the chances of getting these infections.

To participate in this study, you need to be an adult aged 18 to 60 years old living in Australia and have a history of frequent upper respiratory infections. You should be generally healthy and not have serious medical conditions or be taking certain medications. If you join the study, you’ll take either LC-Plasma or a placebo every day, and you’ll need to maintain your usual daily activities without making significant changes. This means sticking to your normal diet and exercise routine, and you shouldn’t travel internationally for more than a month during the study period. If you think you might be eligible and are interested in helping researchers learn more about preventing URTIs, this could be a great opportunity!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18-60 years living in Australia
• • Individuals with a history of recurrent upper respiratory tract infections
• • Able to provide informed consent
• • Generally healthy
• • Agree to not participate in another clinical trial while enrolled in this trial
• • Agree to maintain their usual daily activities without significant changes. This includes not changing their current diet or stopping/starting a new exercise regimen during entire study period
• • Agree not to travel internationally for over 1 month in a single trip during the intervention period (baseline to study completion).
• • Females of childbearing potential must a prescribed form of birth control
• Exclusion Criteria:
• • Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, neurological disorders such as multiple sclerosis.
• • Unstable illness e.g., changing medication/treatment.
• • BMI \<18.5, \>30
• • Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.
• • Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease).
• • Has current symptoms of an acute sickness.
• • Active smokers, nicotine use or drug (prescription or illegal substances) abuse
• • Current alcohol use (\>14 alcoholic drinks week)
• • Allergic to any of the ingredients in the active or placebo formula
• • Pregnant or lactating woman
• • People medically prescribed medications within the last month that would affect the immune and/or the inflammatory response excluding topical steroid use.
• • Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month
• • Participants with cognitive damage
• • Participants with seasonal allergic rhinitis
• • Regular use of antihistamines
• • Individuals deemed unsuitable for participation by the Principal Investigator (PI) of this study.